Edinburgh Biomolecular NMR Unit, EastChem School of Chemistry, University of Edinburgh, Edinburgh EH9 3JJ, UK.
Biochemistry. 2012 Mar 6;51(9):1874-84. doi: 10.1021/bi201689j. Epub 2012 Feb 22.
Numerous complement factor H (FH) mutations predispose patients to atypical hemolytic uremic syndrome (aHUS) and other disorders arising from inadequately regulated complement activation. No unifying structural or mechanistic consequences have been ascribed to these mutants beyond impaired self-cell protection. The S1191L and V1197A mutations toward the C-terminus of FH, which occur in patients singly or together, arose from gene conversion between CFH encoding FH and CFHR1 encoding FH-related 1. We show that neither single nor double mutations structurally perturbed recombinant proteins consisting of the FH C-terminal modules, 19 and 20 (FH19-20), although all three FH19-20 mutants were poor, compared to wild-type FH19-20, at promoting hemolysis of C3b-coated erythrocytes through competition with full-length FH. Indeed, our new crystal structure of the S1191L mutant of FH19-20 complexed with an activation-specific complement fragment, C3d, was nearly identical to that of the wild-type FH19-20:C3d complex, consistent with mutants binding to C3b with wild-type-like affinity. The S1191L mutation enhanced thermal stability of module 20, whereas the V1197A mutation dramatically decreased it. Thus, although mutant proteins were folded at 37 °C, they differ in conformational rigidity. Neither single substitutions nor double substitutions increased measurably the extent of FH19-20 self-association, nor did these mutations significantly affect the affinity of FH19-20 for three glycosaminoglycans, despite critical roles of module 20 in recognizing polyanionic self-surface markers. Unexpectedly, FH19-20 mutants containing Leu1191 self-associated on a heparin-coated surface to a higher degree than on surfaces coated with dermatan or chondroitin sulfates. Thus, potentially disease-related functional distinctions between mutants, and between FH and FH-related 1, may manifest in the presence of specific glycosaminoglycans.
许多补体因子 H (FH) 突变使患者易患非典型溶血尿毒症综合征 (aHUS) 和其他因补体激活调节不当而引起的疾病。除了自我细胞保护受损之外,这些突变体没有被赋予统一的结构或机制后果。位于 FH C 末端的 S1191L 和 V1197A 突变,单独或一起发生在患者中,是由 FH 编码的 CFH 和 FH 相关蛋白 1 编码的 CFHR1 之间的基因转换产生的。我们表明,单个或双突变都没有结构上扰乱由 FH C 末端模块 19 和 20 组成的重组蛋白(FH19-20),尽管与野生型 FH19-20 相比,所有三种 FH19-20 突变体在通过与全长 FH 竞争促进 C3b 包被的红细胞溶血方面都较差。事实上,我们 FH19-20 与激活特异性补体片段 C3d 复合物的 S1191L 突变体的新晶体结构几乎与野生型 FH19-20:C3d 复合物的结构相同,这与突变体与 C3b 的结合具有野生型样亲和力一致。S1191L 突变增强了模块 20 的热稳定性,而 V1197A 突变则显著降低了它。因此,尽管突变蛋白在 37°C 下折叠,但它们在构象刚性上存在差异。单个取代或双取代都没有显著增加 FH19-20 自我缔合的程度,这些突变也没有显著影响 FH19-20 对三种糖胺聚糖的亲和力,尽管模块 20 在识别多阴离子自身表面标记物方面起着关键作用。出乎意料的是,含有 Leu1191 的 FH19-20 突变体在肝素涂覆的表面上自缔合的程度高于涂覆有硫酸皮肤素或硫酸软骨素的表面。因此,突变体之间以及 FH 和 FH 相关蛋白 1 之间可能与疾病相关的功能差异可能表现在特定糖胺聚糖的存在下。